| Name | Title | Contact Details |
|---|---|---|
Brian DuPerre |
Chief Privacy Officer and Cyber Counsel, Deputy General Counsel (U.S. and Global) | Profile |
The MBX Difference: Relationship Based Partnerships Our bottom line in your bottom line. We don`t simply chase the low-hanging fruit. Put simply, our outsourced revenue cycle management will collect more dollars, improve your cash flow, support your physicians and delight your patients. MBX is a growing organization specializing in radiology billing. With MBX, from the start of our relationship to go live, you are in safe hands. Our experienced leadership team, who between them possess over seven decades of working with some of the nation’s leading radiology group practices, has implemented over 300 outsourced revenue cycle management systems. We process millions of procedures per year for practices from coast to coast, as diverse as three provider interventional radiologists in Oregon to a 100+ provider practice in North Carolina. MBX delivers consistent and exceptional revenue cycle management. We bill and collect every possible dollar by capitalizing on operational expertise that is second to none. Our exceptional rate of claims accepted the first time, along with our strong denials management process, ensures that claims are processed quickly and denials handled efficiently and effectively. Our end-to-end service extends from the point at which we receive the physician’s dictated report all the way through to the patient’s account at zero balance – we worry about the billing, you lower your operational overheads.
Computer and Allied Technology Solutions is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genysis Brand Solutions is a customer-centric, turn-key powder and capsule manufacturer.
Metabolon, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Durham, NC. To find more information about Metabolon, Inc., please visit www.metabolon.com
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.